TABLE 2

Stable Stimulant Use at Baseline (Safety Population)

Drug NamePatients (N = 198)
Placebo Plus Stimulant (n = 96)CLON-XR Plus Stimulant (n = 102)
Patients, n (%)Mean Dose, mg/d (Range)Patients, n (%)Mean Dose, mg/d (Range)
Methylphenidates
    Any59 (62)NA59 (58)NA
    Concertaa29 (30)41.9 (18–72)35 (34)38.8 (18–72)
    Focalin XRb10 (10)18.0 (10–40)12 (12)16.7 (5–40)
    Ritalinb9 (9)17.8 (5–60)1 (1)30 (NA)
    Focalinb2 (2)7.5 (5–10)5 (5)20 (10–30)
    Daytranac4 (4)20.0 (10–30)1 (1)15 (NA)
    Metadated4 (4)27.5 (20–50)3 (3)23.3 (20–30)
    Focalin XR and Focalin2 (2)17.5 (5–15) and 10 (15–20)0 (0)0 (NA)
    Ritalin-SRb0 (0)0 (NA)1 (1)80 (NA)
Amphetamines
    Any37 (38)NA43 (42)NA
    Vyvansec13 (14)51.9 (25–100)22 (22)48.6 (20–100)
    Adderall XRc13 (14)21.5 (10–30)17 (17)25.9 (5–60)
    Adderallc9 (9)23.9 (10–30)2 (2)45 (30–60)
    Adderall XR and Adderall1 (1)30 (NA) and 20 (NA)1 (1)25 (NA) and 10 (NA)
    Dexedrinee1 (1)45 (NA)1 (1)20 (NA)
  • a McNeil Pediatrics (Titusville, NJ).

  • b Novartis Pharmaceuticals Corp (East Hanover, NJ).

  • c Shire US Inc (Wayne, PA).

  • d Refers to Metadate CD and Metadate ER, which are both produced by UCB Inc (Smyrna, GA).

  • e GlaxoSmithKline (Research Triangle Park, NC).